WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced ...
Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Sponsored content: Enlarged prostate affects ...
The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.
Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System as a leading minimally invasive treatment for benign ...
Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...
UroLift is a minimally invasive treatment for Benign Prostatic Hyperplasia, a condition that causes an enlarged prostate in men. The procedure uses tiny implants to lift and hold the enlarged prostate ...
In a ground-breaking medical achievement, Nigeria has become the first country in West and Central Africa to successfully perform the UroLift procedure, a revolutionary treatment for benign prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback